Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
- This Is the Growth Decision Founders Shouldn’t Wait to Make
- Tesla says it will start selling Cybercabs by end of year
- 18 Creepy Towns In The US That You Should Avoid
- Trump to throw spotlight on overseas crypto abuses at White House event
- Trump Axed Her CDC Job. Now She Might Help Democrats Take The Georgia House.
- How Better Money Habits Can Lead to a More Comfortable Life
- 19 Things An OCD Therapist Wants You To Know
- From Prompts to Priorities: A Practical AI Visibility Workflow
Browsing: real estate
The $220 billion closed-end universe is the scene of sometimes whacky pricing, including a fair number of good buys and a few really bad ones. There’s…
Pros on CNBC discussed Apple as analysts say they are starting to see signs of slowing demand for the iPhone 15 in China. …
Shares of the iPhone and iPad maker have shed roughly 1.5% this week. …
Early birds who scooped up 1-year CDs in late 2022 face key decisions as those instruments mature. …
Drugstore closures could be a growth opportunity for several traditional retailers looking to gain market share in the health-care sector, according to UBS. …
Several Wall Street analysts reduced their price targets on Tesla ahead of its earnings report due Wednesday. …
Analyst Alex Poon maintained his overweight rating on the China-based technology company and raised his price target by $135 to $150. …
Netflix (NFLX) kicks off tech earnings on Wednesday after the market close. For many, NFLX is the harbinger of how the rest of the sector's earnings…
The crypto market has effectively been on pause as investors wait for a bitcoin ETF. Mike Novogratz says that could come as soon as this year….
Citi maintained its buy rating on the stock but lowered its price target on Nvidia to $575 from $630. That still implies 30.9% upside for the…
Pros on CNBC discussed Nvidia. Shares slumped Tuesday following an announcement that the U.S. plans to curb the export of AI chips to China. …
Analysts are cautious of these names, which are looking costly on a price-earnings basis. …
Meister said in an interview that "the lines are blurring" between the two groups and predicted the future could see a more streamlined approach. …
Rising usage of GLP-1 drugs could drive new members to this gym chain, according to Evercore ISI. …